Other Potential Benefits Wegovy has been shown to decrease the risk of a recurrent major adverse cardiovascular event by 20%
FDA compounding review On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (free base) and AOD-9604 acetate against the 503A Bulks List
Medications, including semaglutide, come with expiration dates for a reason
Contact your GP or IBD team promptly if you experience any of the following whilst taking weight loss injections: Severe or persistent abdominal pain, particularly if different from your usual Crohn's symptoms Significant worsening of diarrhoea or new-onset bloody stools Persistent vomiting preventing adequate fluid or medication intake Signs of dehydration (dark urine, dizziness, reduced urination) Unexplained fever or signs of infection Severe constipation or inability to pass wind (potential obstruction) Symptoms suggesting pancreatitis (severe upper abdominal pain radiating to the back) stop the medication immediately and seek urgent medical attention For severe symptoms, contact NHS 111 for urgent advice or go to A&E/call 999 if you experience severe abdominal pain with vomiting, inability to pass stool or wind, or signs of severe dehydration
While the timing is similar, some research suggests that tirzepatide may have a slightly different side effect profile due to the GIP component, which may help mitigate some of the nausea for certain individuals
